Foghorn Therapeutics FHTX Stock
Foghorn Therapeutics Price Chart
Foghorn Therapeutics FHTX Financial and Trading Overview
| Foghorn Therapeutics stock price | 2.02 USD |
| Previous Close | 2.92 USD |
| Open | 2.8 USD |
| Bid | 3.55 USD x 200 |
| Ask | 6.1 USD x 200 |
| Day's Range | 2 - 2.83 USD |
| 52 Week Range | 1.79 - 7.61 USD |
| Volume | 2.5M USD |
| Avg. Volume | 585.38K USD |
| Market Cap | 119.96M USD |
| Beta (5Y Monthly) | 2.862 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.57 USD |
FHTX Valuation Measures
| Enterprise Value | -4521663 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.9683312 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.2651498 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | -0.123 |
| Enterprise Value/EBITDA | 0.068 |
Trading Information
Foghorn Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.862 |
| 52-Week Change | -35.54% |
| S&P500 52-Week Change | 14.15% |
| 52 Week High | 7.61 USD |
| 52 Week Low | 1.79 USD |
| 50-Day Moving Average | 5.17 USD |
| 200-Day Moving Average | 5.06 USD |
FHTX Share Statistics
| Avg. Volume (3 month) | 585.38K USD |
| Avg. Daily Volume (10-Days) | 1.84M USD |
| Shares Outstanding | 59.39M |
| Float | 28.08M |
| Short Ratio | 4.88 |
| % Held by Insiders | 14.13% |
| % Held by Institutions | 76.67% |
| Shares Short | 1.99M |
| Short % of Float | 6.09% |
| Short % of Shares Outstanding | 3.35% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -175.77% |
| Operating Margin (ttm) | -54.78% |
| Gross Margin | -114.56% |
| EBITDA Margin | -180.60% |
Management Effectiveness
| Return on Assets (ttm) | -19.92% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 36.74M USD |
| Revenue Per Share (ttm) | 0.55 USD |
| Quarterly Revenue Growth (yoy) | 112.70% |
| Gross Profit (ttm) | -42091000 USD |
| EBITDA | -66353000 USD |
| Net Income Avi to Common (ttm) | -64579000 USD |
| Diluted EPS (ttm) | -0.68 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 167.58M USD |
| Total Cash Per Share (mrq) | 2.82 USD |
| Total Debt (mrq) | 43.1M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.362 |
| Book Value Per Share (mrq) | -1.38 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -84241000 USD |
| Levered Free Cash Flow (ttm) | -51954876 USD |
Profile of Foghorn Therapeutics
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 99 Coolidge Avenue |
| ZIP | 02472 |
| Phone | 617 586 3100 |
| Website | https://foghorntx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 106 |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Q&A For Foghorn Therapeutics Stock
What is a current FHTX stock price?
Foghorn Therapeutics FHTX stock price today per share is 2.02 USD.
How to purchase Foghorn Therapeutics stock?
You can buy FHTX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Foghorn Therapeutics?
The stock symbol or ticker of Foghorn Therapeutics is FHTX.
Which industry does the Foghorn Therapeutics company belong to?
The Foghorn Therapeutics industry is Biotechnology.
How many shares does Foghorn Therapeutics have in circulation?
The max supply of Foghorn Therapeutics shares is 59.39M.
What is Foghorn Therapeutics Price to Earnings Ratio (PE Ratio)?
Foghorn Therapeutics PE Ratio is now.
What was Foghorn Therapeutics earnings per share over the trailing 12 months (TTM)?
Foghorn Therapeutics EPS is -0.99 USD over the trailing 12 months.
Which sector does the Foghorn Therapeutics company belong to?
The Foghorn Therapeutics sector is Healthcare.
Foghorn Therapeutics FHTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27190.86 USD — |
+1.19
|
6.86B USD — | 27112.24 USD — | 27353.68 USD — | — - | 6.86B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2166.96 USD — |
+0.27
|
— — | 2163.08 USD — | 2188.89 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6947.64 USD — |
-0.26
|
— — | 6917.55 USD — | 6998.5 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1302.61 USD — |
-0.29
|
— — | 1298.55 USD — | 1311.62 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
